Small HDL form via apo A-I a complex with atrial natriuretic peptide

Biochemical and Biophysical Research Communications

Volumn 315, Issue 1, 2004, Pages 16-21

  Torricelli, Claudia ^a   Capurro, Elisa ^a   Santucci, Annalisa ^a   Paffetti, Alessandro ^a   D'Ambrosio, Chiara ^b   Scaloni, Andrea ^b   Maioli, Emanuela ^a   Pacini, Adriana ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b CNR   (Italy)

Author keywords

Amyloidosis; Apo A I; Atrial natriuretic peptide; HDL; Two dimensional gel electrophoresis

Indexed keywords

APOLIPOPROTEIN A1; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; DIMER; HIGH DENSITY LIPOPROTEIN; IODINE 125; LIPOPROTEIN;

ARTICLE; AUTORADIOGRAPHY; CHROMATOGRAPHY; ELECTROPHORESIS; ELUTION; HEART DISEASE; IMMUNOBLOTTING; INCUBATION TIME; MASS SPECTROMETRY; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; RADIOACTIVITY; TWO DIMENSIONAL ELECTROPHORESIS;

EID: 0842329663     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.01.017     Document Type: Article

References (38)

1. Picken M.M. The changing concepts of amyloid. Arch. Pathol. Lab. Med. 125:2001;38-43.
2. Selkoe D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 271:1996;18295-18298.
3. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med. 4:1998;1318-1320.
4. Buxbaum J., Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol. Oncol. Clin. North. Am. 13:1999;1235-1248.
5. Perutz M.F. Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem. Sci. 24:1999;58-63.
6. Costa P.P., Figueira A.S., Bravo F.R. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc. Natl. Acad. Sci. USA. 75:1978;4499-4503.
7. Drueke T.B. Beta2-microglobulin and amyloidosis. Nephrol. Dial. Transplant. 15:2000;17-24.
8. Jackson G.S., Clarke A.R. Mammalian prion proteins. Curr. Opin. Struct. Biol. 10:2000;69-74.
9. Sletten K., Westermark P., Natvig J.B. Senile cardiac amyloid is related to prealbumin. Scand. J. Immunol. 12:1980;503-506.
10. Steiner I. The prevalence of isolated atrial amyloid. J. Pathol. 153:1987;395-398.
11. Johansson B., Wernstedt C., Westermark P. Atrial natriuretic peptide deposited as atrial amyloid fibrils. Biochem. Biophys. Res. Commun. 148:1987;1087-1092.
12. Barrow C.J., Yasuda A., Kenny P.T., Zagorski M.J. Solution conformations and aggregational properties of synthetic amyloid beta-peptides of Alzheimer's disease. Analysis of circular dichroism spectra. J. Mol. Biol. 225:1992;1075-1093.
13. Westermark P., Eriksson L., Engstrom U., Enestrom S., Sletten K. Prolactin-derived amyloid in the aging pituitary gland. Am. J. Pathol. 150:1997;67-73.
14. Rostagno A., Vidal R., Kaplan B., Chuba J., Kumar A., Elliott J.I., Frangione B., Gallo G., Ghiso J. pH-dependent fibrillogenesis of a VKappaIII Bence Jones protein. Br. J. Haematol. 107:1999;835-843.
15. Wood S.J., Maleeff B., Hart T., Wetzel R. Physical, morphological and functional differences between pH 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Aβ J. Mol. Biol. 256:1996;870-877.
16. Pucci J., Wharton E., Arbustini M., Grasso M., Diegoli P., Needleman M., Vigano J., Polak M. Atrial amyloid deposits in the failing human heart display both atrial and brain natriuretic peptide-like immunoreactivity. J. Pathol. 165:1991;235-241.
17. Rocken C., Peters B., Juenemann G., Saeger W., Klein H.U., Huth C., Roessner A., Goette A. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation. 106:2002;2091-2097.
18. Maioli E., Torricelli C., Santucci A., Pacini A. Molecular assembly of endogenous and synthetic big atrial natriuretic peptide (ANP) and its amyloidogenic implications. Biochim. Biophys. Acta. 1500:2000;31-40.
19. Maioli E., Torricelli C., Santucci A., Martelli P., Pacini A. Plasma factors controlling atrial natriuretic peptide (ANP) aggregation: role of lipoproteins. Biochim. Biophys. Acta. 1536:2001;123-132.
20. Rye K.A., Clay M.A., Barter P.J. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis. 145:1999;227-238.
21. Barter P.J. Hugh Sinclair Lecture: the regulation and remodelling of HDL by plasma factors. Atheroscler. Suppl. 3:2002;39-47.
22. Nanjee M.N., Brinton E.A. Very small apolipoprotein A-I-containing particles from human plasma: isolation and quantification by high-performance size-exclusion chromatography. Clin. Chem. 46:2000;207-223.
23. Tall A.R. An overview of reverse cholesterol transport. Eur. Heart J. 19(Suppl. A):1998;A31-A35.
24. Nofer J.R., Kehrel B., Fobker M., Levkau B., Assmann G., von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 161:2002;1-16.
25. Koudinov A., Matsubara E., Frangione B., Ghiso J. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma. Biochem. Biophys. Res. Commun. 205:1994;1164-1171.
26. Koudinov A.R., Berezov T.T., Kumar A., Koudinova N.V. Alzheimer's amyloid β interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin. Chim. Acta. 270:1998;75-84.
27. Sousa M.M., Berglund L., Saraiva M.J. Transthyretin in high density lipoproteins: association with apolipoprotein A-I. J. Lipid. Res. 41:2000;58-65.
28. Trabalzini L., Paffetti A., Scaloni A., Talamo F., Ferro E., Coratza G., Bovalini L., Lusini P., Martelli P., Santucci A. Proteomic response to physiological fermentation stresses in a wild-type wine strain of Saccharomyces cerevisiae. Biochem. J. 370:2003;35-46.
29. Talamo F., D'Ambrosio C., Arena S., Del Vecchio P., Ledda L., Zehender G., Ferrara L., Scaloni A. Proteins from bovine tissues and biological fluids: defining a reference electrophoresis map for liver, kidney, muscle, plasma and red blood cells. Proteomics. 3:2003;440-460.
30. Ladu M.J., Reardon C., Van Eldik L., Fagan A.M., Bu G., Holtzman D., Gets G.S. Lipoproteins in the central nervous system. Ann. N. Y. Acad. Sci. 903:2000;167-175.
31. Naiki H., Higuchi K., Nakakuki K., Takeda T. Kinetic analysis of amyloid fibril polymerization in vitro. Lab. Invest. 65:1991;104-110.
32. Koudinov A.R., Berezov T.T., Koudinova N.V. The levels of soluble amyloid beta in different high density lipoprotein subfractions distinguish Alzheimer's and normal aging cerebrospinal fluid: implication for brain cholesterol pathology? Neurosci. Lett. 314:2001;115-118.
33. Asztalos B.F., Sloop C.H., Wong L., Roheim P.S. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim. Biophys. Acta. 1169:1993;291-300.
34. Curtiss L.K., Bonnet D.J., Rye K.A. The conformation of apolipoprotein A-I in high-density lipoproteins is influenced by core lipid composition and particle size: a surface plasmon resonance study. Biochemistry. 39:2000;5712-5721.
35. Shuvaev V.V., Siest G. Interaction between human amphipathic apolipoproteins, amyloid beta-peptide: surface plasmon resonance studies. FEBS Lett. 383:1996;9-12.
36. Bovy P.R. Structure activity in the atrial natriuretic peptide (ANP) family. Med. Res. Rev. 10:1990;115-142.
37. Wilkins D.K., Dobson C.M., Gross M. Biophysical studies of the development of amyloid fibrils from a peptide fragment of cold shock protein B. Eur. J. Biochem. 267:2000;2609-2616.
38. Chiti F., Webster P., Taddei N., Clark A., Stefani M., Ramponi G., Dobson C.M. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl. Acad. Sci. USA. 96:1999;3590-3594.